Dr. Corn on Sequencing Agents for Patients With mCRPC

Paul G. Corn, MD, PhD
Published: Thursday, Mar 09, 2017



Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

There is an increasing number of agents that are FDA approved to treat patients with mCRPC, says Corn, adding that this is an exciting time to be a prostate cancer clinician and researcher because of the number of successful agents.

However, the amount of new agents has created sequencing and combination challenges. Therefore, an exciting area of research is the development of predictive biomarkers to individualize therapies for patients. At The University of Texas MD Anderson Cancer Center, Corn says that physicians frequent perform tumor biopsies to understand the heterogeneity of mCRPC.
 


Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

There is an increasing number of agents that are FDA approved to treat patients with mCRPC, says Corn, adding that this is an exciting time to be a prostate cancer clinician and researcher because of the number of successful agents.

However, the amount of new agents has created sequencing and combination challenges. Therefore, an exciting area of research is the development of predictive biomarkers to individualize therapies for patients. At The University of Texas MD Anderson Cancer Center, Corn says that physicians frequent perform tumor biopsies to understand the heterogeneity of mCRPC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x